Redmile Group, LLC - Sep 19, 2023 Form 4 Insider Report for RayzeBio, Inc. (RYZB)

Role: 10%+ Owner
Signature: By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC
Stock symbol: RYZB
Transactions as of: Sep 19, 2023
Transactions value $: $0
Form type: 4
Date filed: 9/21/2023, 09:30 PM
Previous filing: Sep 14, 2023
Next filing: Oct 3, 2023

Transactions Table

Type	Sym	Class	Transaction	Shares	Change %	Shares After	Date	Ownership	Footnotes
transaction	RYZB	Common Stock	Conversion of derivative security	+865K		865K	Sep 19, 2023	See Footnote	F1, F2
transaction	RYZB	Common Stock	Conversion of derivative security	+495K	+57.22%	1.36M	Sep 19, 2023	See Footnote	F1, F2
transaction	RYZB	Common Stock	Conversion of derivative security	+499K	+36.68%	1.86M	Sep 19, 2023	See Footnote	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Date	Underlying Class	Amount	Ownership	Footnotes
transaction	RYZB	Series B Preferred Stock	Conversion of derivative security	$0	-865K	-100%	$0.00^*	Sep 19, 2023	Common Stock	865K	See Footnote	F1, F2
transaction	RYZB	Series C Preferred Stock	Conversion of derivative security	$0	-432K	-100%	$0.00^*	Sep 19, 2023	Common Stock	495K	See Footnote	F1, F2
transaction	RYZB	Series D Preferred Stock	Conversion of derivative security	$0	-499K	-100%	$0.00^*	Sep 19, 2023	Common Stock	499K	See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Redmile Group, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date.
F2	These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Content

The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date.

These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.